Kumar Ankit, Singh Pratyaksha, Singh Ekampreet, Jain Monika, Muthukumaran Jayaraman, Singh Amit Kumar
Department of Biotechnology, Sharda School of Engineering and Technology, Sharda University, Greater Noida, India.
School of Biotechnology, Gautam Budha University, Greater Noida, India.
J Biomol Struct Dyn. 2024 Mar 14:1-15. doi: 10.1080/07391102.2024.2325661.
The opportunistic bacterium , which belongs to ESKAPE group of pathogenic bacteria, is leading cause of infections associated with gram-negative bacteria. causes severe diseases, such as VAP (ventilator-associated pneumonia), meningitis, and UTI (urinary tract infections) among the nosocomial infections contracted in hospitals. The high infection rate and growing resistance to the vast array of antibiotics makes it paramount to look for new therapeutic strategies against this pathogen. The most promising therapeutic targets are the proteins involved in the synthesis of peptidoglycan which is chief component of bacterial cell wall, MurE is one of those enzymes and is responsible for the addition of one unit of meso-diaminopimelic acid (meso-A2pm) to the nucleotide precursor, UDPMurNAc-L-Ala-D-Glu, and aids in the formation of crosslinker pentapeptide chain. The three-dimensional structure of MurE was modelled using homology modelling technique and then vHTS was performed using this model against Approved Drug Library on DrugRep server using AutoDock Vina. Out of 500 drug molecules, two were selected based on estimated binding affinity, interaction pattern, interacting residues, etc. The selected drug molecules are DB12887 (Tazemetostat) and DB13879 (Glecaprevir). Then, MD simulations were performed on native MurE and its complexes with ligands to examine their dynamical behaviour, stability, integrity, compactness, and folding properties. The protein-ligand complexes were then subjected to binding free energy calculations using the MM/PBSA-based binding free energy analysis and the values are -109.788 ± 8.03 and -152.753 ± 11.98 kcal for MurE-DB12887 and MurE-DB13879 complex, respectively. All the analysis performed on MD trajectories for the complexes of these ligands with protein provided plenty of dependable evidences to consider these molecules for inhibition of MurE enzyme from
这种机会致病菌属于ESKAPE病原菌组,是革兰氏阴性菌相关感染的主要原因。它会引发严重疾病,如医院获得性感染中的呼吸机相关性肺炎(VAP)、脑膜炎和尿路感染(UTI)。其高感染率以及对大量抗生素不断增加的耐药性使得寻找针对这种病原体的新治疗策略变得至关重要。最有前景的治疗靶点是参与肽聚糖合成的蛋白质,肽聚糖是细菌细胞壁的主要成分,MurE就是其中一种酶,负责将一个内消旋二氨基庚二酸(meso-A2pm)单位添加到核苷酸前体UDP-MurNAc-L-Ala-D-Glu上,并有助于形成交联五肽链。利用同源建模技术对MurE的三维结构进行建模,然后使用该模型在DrugRep服务器上针对批准药物库,利用AutoDock Vina进行虚拟高通量筛选(vHTS)。在500个药物分子中,根据估计的结合亲和力、相互作用模式、相互作用残基等选择了两个。所选药物分子为DB12887(他泽司他)和DB13879(格卡瑞韦)。然后,对天然MurE及其与配体的复合物进行分子动力学(MD)模拟,以研究它们的动力学行为、稳定性、完整性、紧密性和折叠特性。接着,使用基于MM/PBSA的结合自由能分析对蛋白质-配体复合物进行结合自由能计算,MurE-DB12887和MurE-DB13879复合物的值分别为-109.788±8.03和-152.753±11.98千卡。对这些配体与蛋白质复合物的MD轨迹进行的所有分析提供了大量可靠证据,以考虑将这些分子用于抑制MurE酶